News

NICE recommends Rinvoq to treat severe Rheumatoid Arthritis.- AbbVie

Read time: 1 mins

Published:3rd Feb 2020

The National Institute for Health and Care Excellence (NICE) has recommended Rinvoq (upadacitinib) from AbbVie together with standard-of-care methotrexate, for coverage on the National Health Service as a treatment for severe rheumatoid arthritis, according to draft guidance. Rinvoq, with a list price of £805.56 ($1,058.06) per 28-day pack and average annual cost per patient of £10,508 ($13,801), will come with a confidential discount. Despite the success in severe RA, NICE did not accept Rinvoq's application to treat moderate RA, stating that the drug's price didn't meet its cost-effectiveness standard in that indication.

Condition: Rheumatoid Arthritis

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Metoject subcutaneous injection pen (methotrexate) pen -type autoinjector approved in Japan

Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft für klinische Spezialpräparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector “Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL” (methotrexate)

1 mins

Drug news

Galapagos signs agreement to transfer Jyseleca business to Alfasigma.

Galapagos NV and Alfasigma S.p.A. announced that they have signed an agreement to transfer Galapagos’ Jyseleca (filgotinib) business to Alfasigma, marking a significant milestone in Galapagos’ transformation into an innovative biotechnology company with a best-in-class research and development pipeline aimed at addressing high unmet patient needs in immunology and oncology

1 min

Drug news

Post hoc analysis showed meaningful efficacy of certolizumab pegol for RA patients with high Rheumatoid Factor (RF) levels.- UCB.

UCB, will present a post hoc analysis of the EXXELERATE trial examining the efficacy of certolizumab pegol and adalimumab in patients with rheumatoid arthritis (RA) with high rheumatoid factor (RF) levels . The data are being presented at the American College of Rheumatology (ACR) Convergence 2023 in San Diego, U.S., November 10–15.

2 min

See all news